Skye Bioscience (SKYE)

Executive Summary

Skye Bioscience is a publicly traded biopharmaceutical company developing proprietary cannabinoid derivatives for diseases with high unmet medical needs, including glaucoma and obesity. The company's lead candidate, SBI-100, an ophthalmic emulsion for primary open-angle glaucoma and ocular hypertension, recently completed a Phase 2 trial (NCT06144918) with data expected to inform a Phase 3 program. Additionally, Skye is advancing nimacimab, a peripherally restricted anti-CB1 antibody, in a Phase 2 trial for obesity (NCT06577090), which is actively recruiting and expected to complete in early 2027. With a market valuation of approximately $31 million, Skye represents a high-risk, high-reward opportunity in the cannabinoid therapeutics space, leveraging its proprietary platform to target large markets where current treatments have significant limitations. The company's near-term value hinges on successful clinical data readouts and potential partnerships.

Upcoming Catalysts (preview)

• H1 2027Phase 2 obesity trial data readout (nimacimab)35% success
• H2 2026Initiation of Phase 3 program for SBI-100 in glaucoma50% success
• TBDPotential partnership or licensing deal for cannabinoid pipeline20% success